1,904
Views
0
CrossRef citations to date
0
Altmetric
Research Article

Baricitinib provides rapid and sustained improvements in absolute EASI and SCORAD outcomes in adults with moderate-to-severe atopic dermatitis

, , , , , , & show all
Article: 2216322 | Received 30 Jan 2023, Accepted 20 Mar 2023, Published online: 21 Jun 2023

Reprints and Permissions

Permission is granted subject to the terms of the License under which the work was published. Permission will be required if your reuse is not covered by the terms of the License.

To request a reprint or commercial or derivative permissions for this article, please click on the relevant link below.

For more information please visit our Permissions help page.